In 2018, burosumab, a fully human monoclonal antibody that binds to and inhibits excessive FGF23 activity and raises levels of 1,25 dihydroxyvitamin D, was approved by health authorities in the European Union and the USA for the treatment of patients with symptomatic XLH, on the basis of encouraging results of clinical trials [2,23,24,25]. Here, FGF23 is linked to X-linked hypophosphatemia.